Epidemiological studies support an association between elevated circulating levels of IGF-I and reduced IGFBP-3 levels in the circulation and increased risk of breast [20,21], prostate [22], and colorectal cancer or adenoma [23-26]. Here, IGFBP3 is linked to adenoma.